152 related articles for article (PubMed ID: 10999468)
21. Pyrazinoindolone inhibitors of MAPKAP-K2.
Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
[TBL] [Abstract][Full Text] [Related]
22. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
[TBL] [Abstract][Full Text] [Related]
23. Pyrroles and other heterocycles as inhibitors of p38 kinase.
de Laszlo SE; Visco D; Agarwal L; Chang L; Chin J; Croft G; Forsyth A; Fletcher D; Frantz B; Hacker C; Hanlon W; Harper C; Kostura M; Li B; Luell S; MacCoss M; Mantlo N; O'Neill EA; Orevillo C; Pang M; Parsons J; Rolando A; Sahly Y; Sidler K; O'Keefe SJ
Bioorg Med Chem Lett; 1998 Oct; 8(19):2689-94. PubMed ID: 9873604
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of novel 4,5-diphenylthiazole derivatives as potential acyl-CoA:cholesterol O-acyltransferase inhibitors.
Romeo G; Salerno L; Milla P; Siracusa M; Cattel L; Russo F
Pharmazie; 1999 Jan; 54(1):19-23. PubMed ID: 9987793
[TBL] [Abstract][Full Text] [Related]
25. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.
Hynes J; Leftheri K
Curr Top Med Chem; 2005; 5(10):967-85. PubMed ID: 16178741
[TBL] [Abstract][Full Text] [Related]
26. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.
Smith RA; Barbosa J; Blum CL; Bobko MA; Caringal YV; Dally R; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Lowinger TB; Lyons J; Marsh V; Rogers DH; Swartz S; Walling T; Wild H
Bioorg Med Chem Lett; 2001 Oct; 11(20):2775-8. PubMed ID: 11591521
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
28. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
29. A novel competitive class of α-glucosidase inhibitors: (E)-1-phenyl-3-(4-styrylphenyl)urea derivatives.
Kim JY; Lee JW; Kim YS; Lee Y; Ryu YB; Kim S; Ryu HW; Curtis-Long MJ; Lee KW; Lee WS; Park KH
Chembiochem; 2010 Oct; 11(15):2125-31. PubMed ID: 20827790
[TBL] [Abstract][Full Text] [Related]
30. Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Choi C; Li JH; Vaal M; Thomas C; Limburg D; Wu YQ; Chen Y; Soni R; Scott C; Ross DT; Guo H; Howorth P; Valentine H; Liang S; Spicer D; Fuller M; Steiner J; Hamilton GS
Bioorg Med Chem Lett; 2002 May; 12(10):1421-8. PubMed ID: 11992790
[TBL] [Abstract][Full Text] [Related]
31. N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.
Oguro Y; Miyamoto N; Takagi T; Okada K; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
Bioorg Med Chem; 2010 Oct; 18(20):7150-63. PubMed ID: 20833551
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
[TBL] [Abstract][Full Text] [Related]
34. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD
J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481
[TBL] [Abstract][Full Text] [Related]
35. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
36. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
37. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
McKenna JM; Halley F; Souness JE; McLay IM; Pickett SD; Collis AJ; Page K; Ahmed I
J Med Chem; 2002 May; 45(11):2173-84. PubMed ID: 12014955
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
[TBL] [Abstract][Full Text] [Related]
39. Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry.
Barnes MJ; Conroy R; Miller DJ; Mills JS; Montana JG; Pooni PK; Showell GA; Walsh LM; Warneck JB
Bioorg Med Chem Lett; 2007 Jan; 17(2):354-7. PubMed ID: 17095218
[TBL] [Abstract][Full Text] [Related]
40. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
